Clearmind Medicine Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CMND Nasdaq 2830 www.clearmindmedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Clearmind Medicine Inc.

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial - Feb 9th, 2026 6:17 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Feb 8th, 2026 1:50 pm
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI - Feb 6th, 2026 5:55 am
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation - Feb 6th, 2026 5:55 am
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments - Feb 3rd, 2026 6:00 am
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 - Jan 20th, 2026 2:20 pm
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 - Jan 14th, 2026 6:55 am
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement - Dec 31st, 2025 7:10 am
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth - Dec 24th, 2025 7:15 am
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 - Dec 16th, 2025 6:45 am
Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment - Dec 12th, 2025 6:32 am
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Dec 12th, 2025 4:32 am
Clearmind Medicine Announces 1-for-40 Reverse Share Split - Dec 10th, 2025 2:15 pm
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification - Dec 5th, 2025 3:00 pm
BC-Most Active Stocks - Dec 2nd, 2025 8:30 am
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder - Dec 2nd, 2025 5:57 am
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial - Dec 1st, 2025 6:56 am
Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial - Nov 25th, 2025 5:17 am
Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review - Nov 24th, 2025 6:51 am
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - Nov 20th, 2025 4:42 am